{"id":202089,"name":"CELGENE CORPORATION","slug":"celgene-corporation","state":"NJ","country":"United States of America","description":"Global biopharmaceutical company","totalSpending":450000,"filings":9,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":250000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["SPLITOAK STRATEGIES LLC"],"lobbyists":["SARAH EGGE","AMY JENSEN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)","Executive Office of the President (EOP)","Office of Management & Budget (OMB)","White House Office","Centers For Medicare and Medicaid Services (CMS)"],"sampleDescriptions":["HR 2212/S 974 - CREATES Act; HR 2051 - FAST Generics Act; Medicare Reimbursement for Transformative Therapies","HR 2212/S 974 - CREATES Act; HR 2051 - FAST Generics Act; Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies","HR 2212/S 974 - CREATES Act; HR 2051 - FAST Generics Act; Medicare Coverage and Reimbursement for Transformative Therapies","HR 2212/S 974 - CREATES Act; HR 2051 - FAST Generics Act; Medicare Coverage and Reimbursement for Transformative Therapies","S. 340/H.R. 965 CREATES Act"]}